Cargando…

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

BACKGROUND: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy of programmed death-1 (PD-1) inhibition. METHODS: A pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Kwang-Yu, Chiang, Nai-Jung, Wu, Shang-Yin, Yen, Chia-Jui, Chen, Shang-Hung, Yeh, Yu-Min, Li, Chien-Feng, Feng, Xiaoxing, Wu, Katherine, Johnston, Amanda, Bomalaski, John S., Wu, Bor-Wen, Gao, Jianjun, Subudhi, Sumit K., Kaseb, Ahmed O., Blando, Jorge M., Yadav, Shalini S., Szlosarek, Peter W., Chen, Li-Tzong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276661/ https://www.ncbi.nlm.nih.gov/pubmed/34290906 http://dx.doi.org/10.1080/2162402X.2021.1943253

Ejemplares similares

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)
por: Burrows, Natalie, et al.
Publicado: (2016)

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
por: Przystal, Justyna Magdalena, et al.
Publicado: (2018)

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
por: Yang, T-S, et al.
Publicado: (2010)

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
por: Tsai, Hui-Jen, et al.
Publicado: (2017)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism
por: Zhang, Yiming, et al.
Publicado: (2022)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
por: Chan, Pui Ying, et al.
Publicado: (2022)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Pegylated Arginine Deiminase Downregulates Colitis in Murine Models
por: Oz, Helieh S., et al.
Publicado: (2012)

PEGylation increases antitumoral activity of arginine deiminase of Streptococcus pyogenes
por: Schwarz, Rico, et al.
Publicado: (2021)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
por: Tsai, Hui‐Jen, et al.
Publicado: (2021)

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
por: Yao, Shuyang, et al.
Publicado: (2021)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
por: Daylami, Rouzbeh, et al.
Publicado: (2014)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

A protocol to induce systemic autophagy and increase energy metabolism in mice using PEGylated arginine deiminase
por: Zhang, Yiming, et al.
Publicado: (2022)

Depletion of Arginine by Recombinant Arginine Deiminase Induces nNOS-Activated Neurotoxicity in Neuroblastoma Cells
por: Lin, Shan-Erh, et al.
Publicado: (2014)

Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
por: Rogers, Leonard C., et al.
Publicado: (2023)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Arginine metabolism and the role of arginine deiminase-producing microorganisms in kimchi fermentation
por: Jung, Sera, et al.
Publicado: (2022)

PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration
por: Brin, Elena, et al.
Publicado: (2017)

Molecular mechanism of substrate selectivity of the arginine-agmatine Antiporter AdiC
por: Krammer, Eva-Maria, et al.
Publicado: (2018)

Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase
por: Fernández-Lainez, Cynthia, et al.
Publicado: (2021)

Streptococcal Arginine Deiminase Inhibits T Lymphocyte Differentiation In Vitro
por: Starikova, Eleonora A., et al.
Publicado: (2023)

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
por: Park, I-S, et al.
Publicado: (2003)

Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor
por: Aliko, Ardita, et al.
Publicado: (2019)

Acquisition of the arginine deiminase system benefits epiparasitic Saccharibacteria and their host bacteria in a mammalian niche environment
por: Tian, Jing, et al.
Publicado: (2022)

Convergent evolution of the arginine deiminase pathway: the ArcD and ArcE arginine/ornithine exchangers
por: Noens, Elke E. E., et al.
Publicado: (2016)

Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer
por: Beato, Miguel, et al.
Publicado: (2020)

Evaluation of the PEG Density in the PEGylated Chitosan Nanoparticles as a Drug Carrier for Curcumin and Mitoxantrone
por: Chen, Yao, et al.
Publicado: (2018)

Adi Armoni
por: Armoni, Adi
Publicado: (2022)

Adie's Syndrome
por: Marmion, Vincent
Publicado: (1975)

Structural Characterization of the Enzymes Composing the Arginine Deiminase Pathway in Mycoplasma penetrans
por: Gallego, Pablo, et al.
Publicado: (2012)

Arginine deiminase pathway enzymes: evolutionary history in metamonads and other eukaryotes
por: Novák, Lukáš, et al.
Publicado: (2016)

Protein arginine deiminase 4 antagonizes methylglyoxal-induced histone glycation
por: Zheng, Qingfei, et al.
Publicado: (2020)

The role of protein arginine deiminase 4-dependent neutrophil extracellular traps formation in ulcerative colitis
por: Wang, Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_484ch6d8c7u47tkm3vb7vnmlaj